Core Insights - 旺山旺水-B (2630.HK) debuted on the Hong Kong Stock Exchange today, opening at 95 HKD, a 184.69% increase from its IPO price of 33.37 HKD, resulting in a market capitalization of 15.9 billion HKD [1] - The IPO was highly successful, with the Hong Kong public offering being oversubscribed by 6,238.42 times and the international offering by 16.87 times, raising a net amount of 527.36 million HKD [1] Company Overview - 旺山旺水 is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing small molecule drugs in strategic therapeutic areas, specifically neuropsychiatric and reproductive health [1] - The company has developed two core products: LV232, a dual-target 5-HTT/5-HT3 receptor modulator for treating major depressive disorder, and TPN171, a PDE5 inhibitor for treating erectile dysfunction [1] - Additionally, the company has four candidate drugs in clinical stages and three in preclinical stages [1]
港股异动丨旺山旺水首日上市高开184%